Drug Trial Radar · NCT07711470
Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC
Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Dec 31, 2028
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, prospective Phase II study investigates a response-adapted organ-preservation strategy in patients with resectable esophageal squamous cell carcinoma (ESCC). Participants will receive two cycles of induction chemoimmunotherapy with sugemalimab, nab-paclitaxel, and cisplatin. Patients who achieve a major clinical response will receive definitive radiotherapy plus sugemalimab followed by maintenance sugemalimab, while non-major responders will undergo surgery-based treatment strategies. The study aims to evaluate the efficacy and safety of this tailored treatment approach, with the primary endpoint being 2-year progression-free survival. Secondary and exploratory objectives include survival outcomes, quality of life, nutritional status.
Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Sugemalimab and ChemotherapyDrug
Sugemalimab 1200 mg administered intravenously every 3 weeks as induction, and maintenance immunotherapy.
Nab-paclitaxelDrug
125 mg/m² administered intravenously on Days 1 and 8 every 3 weeks during induction therapy.
CisplatinDrug
75 mg/m² administered intravenously on Day 1 every 3 weeks during induction therapy.
Radiation TherapyRadiation
IMRT: PTV 41.4 Gy/23f,PGTV 49.45 Gy/23f
Primary outcomes
What the sponsor says the trial is designed to measure.
- 2-year PFS rateTime frame: Up to 2 years after initiation of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.